Madrigal Pharmaceuticals, Inc., planned to announce topline results from the Phase 3 MAESTRO-NAFLD-1 study of resmetirom on January 31, 2022. Madrigal's lead candidate, resmetirom, is a first-in-class, orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR)-ß selective agonist that is currently in two Phase 3 clinical studies, MAESTRO-NASH and MAESTRO-NAFLD-1, designed to demonstrate multiple benefits in NASH (non-alcoholic steatohepatitis) patients.